| Literature DB >> 26471977 |
Martin Clauss1, Lilianna Bolliger1, Daniel Brandenberger1, Peter E Ochsner1, Thomas Ilchmann1.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2015 PMID: 26471977 PMCID: PMC4812072 DOI: 10.3109/17453674.2015.1104153
Source DB: PubMed Journal: Acta Orthop ISSN: 1745-3674 Impact factor: 3.717
Figure 1.The Virtec (VSS) straight stem and the Müller (MSS) straight stem (lateral version).
Demographics
| Müller straight stem (MSS) | Virtec straight stem (VSS) | |
|---|---|---|
| Number of hips | 356 | 355 |
| Sex (male/female) | 202/154 | 217/138 |
| Mean age at surgery (SD) | 69 (10) | 69 (11) |
Diagnosis at operation
| Müller straight stem (MSS) | Virtec straight stem (VSS) | |
|---|---|---|
| Osteoarthritis | 269 | 257 |
| Rheumatoid arthritis | 5 | 4 |
| Femoral neck fracture | 17 | 19 |
| Dysplasia | 44 | 49 |
| Other | 21 | 26 |
Acetabular components
| Müller straight stem (MSS) | Virtec straight stem (VSS) | |
|---|---|---|
| SL cup | 271 | 272 |
| SL cup with Metasul PE | 26 | 33 |
| ARR ring (Müller) | 51 | 45 |
| AP cage (Burch-Schneider) | 2 | 1 |
| Polyethylene cemented | 6 | 4 |
Figure 2.Survival status at latest follow-up with the 399 included radiographic examinations for osteolysis analysis and the excluded radiographic examinations due to missing data or follow-up time that was too short.
Risk of revision and osteolysis in THA patients with the Virtec straight stem (VSS) or the Müller straight stem (MSS)
| Risk analysis | MSS events % | VSS events % | HR (95% CI) | p-value | ||
|---|---|---|---|---|---|---|
| Any revision | (n = 356) | (n = 355) | ||||
| any exchange | 32 | 9.0 | 22 | 6.2 | 0.7 (0.4–1.2) | 0.2 |
| Stem revision | ||||||
| aseptic | 15 | 4.2 | 9 | 2.5 | 0.6 (0.3–1.3) | 0.2 |
| any cause | 24 | 6.7 | 16 | 4.5 | 0.7 (0.3–1.2) | 0.2 |
| worst case | 33 | 9.3 | 26 | 7.3 | 0.8 (0.5–1.3) | 0.3 |
| Osteolysis | (n = 196) | (n = 203) | ||||
| any | 40 | 20 | 28 | 14 | 0.7 (0.4–1.1) | 0.1 |
| G1 | 10 | 5 | 4 | 2 | 0.4 (0.1–1.3) | 0.1 |
| G2 | 23 | 12 | 12 | 6 | 0.5 (0.3–1.0) | 0.06 |
| G3 | 15 | 8 | 7 | 3 | 0.5 (0.2–1.1) | 0.09 |
| G4 | 7 | 4 | 4 | 2 | 0.6 (0.2–2.0) | 0.4 |
| G5 | 18 | 9 | 10 | 5 | 0.5 (0.3–1.2) | 0.1 |
| G6 | 26 | 13 | 15 | 7 | 0.6 (0.3–1.1) | 0.07 |
| G7 | 23 | 12 | 11 | 5 | 0.5 (0.2–1.0) | 0.04 |
Revisions (74 hips)
| Müller straight stem (MSS) | Virtec straight stem (VSS) | |||||
|---|---|---|---|---|---|---|
| Revised components | n | % | Time to revision | n | % | Time to revision |
| Both components | 13 | 3.7 | 4.4 (0.8–16.3) | 9 | 2.5 | 4.2 (1.7–11.1) |
| Stem | 11 | 3.1 | 7.1 (1.9–14.2) | 7 | 2.0 | 6.0 (1.0–12.0) |
| Cup | 7 | 2.0 | 3.5 (1.5–7.8) | 3 | 0.8 | 8.0 (3.7–10.6) |
| Only inlay | 1 | 0.3 | 3.3 | 3 | 0.8 | 0.5 (0.3–0.7) |
| Reoperation | 12 | 3.4 | 3.2 (0.3–11.4) | 8 | 2.3 | 4.6 (0.1–13.3) |
without component exchange
Stem revisions for different reasons (40 hips)
| Müller straight stem (MSS) | Virtec straight stem (VSS) | |||||
|---|---|---|---|---|---|---|
| Revised components | n | % | Time to revision | n | % | Time to revision |
| Aseptic loosening | 15 | 4.1 | 7.2 (1.3–16.3) | 9 | 2.5 | 6.3 (1.0–12.0) |
| stem | 11 | 2.2 | 6.8 (4.2–12.1) | 6 | 1.4 | 6.5 (3.8–12.0) |
| both components | 4 | 0.6 | 2.6 (1.3–4.0) | 3 | 0.6 | 2.9 (2.8–3.0) |
| Infection | 8 | 2.2 | 3.7 (0.8–9.9) | 5 | 1.4 | 3.7 (1.7–9.4) |
| Periprosthetic fracture | 1 | 0.3 | 2.4 | 1 | 0.3 | 8.1 |
| Malposition | 0 | – | – | 1 | 0.3 | 2.5 |
Figure 3.Kaplan-Meier survival curve with component revision for any reason as endpoint.
Figure 4.Kaplan-Meier survival curve with revision for aseptic loosening of the stem as endpoint.